NASDAQ: IMVTImmunovant Inc Stock
$25.39-1.02 (-3.86%)
Updated May 31, 2024
IMVT Price
$25.39
Fair Value Price
$4.60
Market Cap
$3.71B
52 Week Low
$18.16
52 Week High
$45.58
P/E
-13.51x
P/B
6x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$259.34M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
-$214M
Beta
0.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMVT Overview
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMVT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMVT ($25.39) is overvalued by 451.99% relative to our estimate of its Fair Value price of $4.60 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMVT ($25.39) is not significantly undervalued (451.99%) relative to our estimate of its Fair Value price of $4.60 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMVT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMVT due diligence checks available for Premium users.
Be the first to know about important IMVT news, forecast changes, insider trades & much more!
IMVT News
Valuation
IMVT fair value
Fair Value of IMVT stock based on Discounted Cash Flow (DCF)
Price
$25.39
Fair Value
$4.60
Overvalued by
451.99%
IMVT ($25.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMVT ($25.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMVT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMVT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.51x
Industry
-14.17x
Market
28.44x
IMVT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6x
Industry
6.04x
IMVT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMVT's financial health
Profit margin
Revenue
$0.0
Net Income
-$75.3M
Profit Margin
0%
IMVT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$666.4M
Liabilities
$48.6M
Debt to equity
0.08
IMVT's short-term assets ($665.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMVT's short-term assets ($665.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMVT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMVT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$59.7M
Investing
-$150.0k
Financing
$1.5M
IMVT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMVT vs Biotech Stocks
Immunovant Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.